Onyx is important embolic material in the endovascular treatment of intracranial dural arteriovenous fistula (DAVF). However, its impact on DAVF occlusion rates, morbidity, mortality, and complication rates is not fully examined. OBJECTIVE: To improve understanding of safety and effectiveness profiles associated with transarterial endovascular treatment using Onyx for intracranial DAVF METHODS: We analyzed data from our prospective clinical registry and conducted a systematic review of all previous transarterial embolization studies using Onyx published between January 2005 and December 2015 in MEDLINE and EMBASE. RESULTS: In the prospective study, 41 transarterial procedures were performed in 33 consecutive patients harboring 36 DAVFs. Complete initial exclusion was obtained in 32 of 36 (88.9%) fistulas; 31 fistulas were followed up showing 4 (12.9%) recurrences. Procedure-related morbidity and mortality were 3% and 0%, respectively. The literature review identified 19 studies involving a total of 425 patients with 463 DAVFs. Meta-analysis, including our registry data, showed an initial complete occlusion rate of 82% (95% confidence interval [CI]: 74%, 88%; I 2 , 70.6%), and recurrence rate at midterm of 2% (95% CI: 0%, 5%; I 2 , 21.5%). Pooled postoperative neurological deficit, procedure-related morbidity, and mortality rates were 4% (95% CI: 2%, 6%; I 2 , 0%), 3% (95% CI: 1%, 5%; I 2 , 0%), and 0%, respectively. CONCLUSION: This meta-analysis suggests that transarterial embolization with Onyx is a safe treatment modality for DAVFs. Although Onyx showed a low recurrence rate at midterm, the long-term risk is poorly addressed in our study and should warrant a longer follow-up.
I
ntracranial dural arteriovenous fistula (DAVF) accounts for 10% to 15% of intracranial vascular malformations and are treated by endovascular approach in the majority of cases. 1 Ethylene vinyl alcohol/dimethyl sulfoxide polymer (Onyx, EV3, Irvine, California) is an important liquid embolic ABBREVIATIONS: BCA, butyl-cyanoacrylate; CI, confidence interval; DAVF, dural arteriovenous fistula; DSA, digital subtraction angiography; EVT, endovascular treatment; mRS, modified Rankin score Supplemental digital content is available for this article at www.neurosurgery-online.com. material in the endovascular treatment (EVT) of intracranial DAVFs. Onyx embolic material has been extensively used due to its nonadhesive properties, allowing prolonged injection times with good lesion penetration, and convenient control for the operator. 2 Since the introduction of Onyx in 2005, several single-center studies have demonstrated acceptable rates of DAVF occlusion, morbidity, and mortality for patients treated with Onyx via transarterial approach. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Improved understanding of safety and effectiveness profiles associated with Onyx treatment of intracranial DAVF is needed. Thus, we analyzed data from our prospective clinical registry and conducted a systematic review and meta-analysis of the literature with special interest in intracranial DAVF occlusion rates,
FIGURE 1. Demonstration of a case treated with transarterial embolization with Onyx (EV3). A and B, Pretreatment lateral and anterior angiograms after external carotid artery injection show a Cognard type II a+b DAVF centered along the left lateral sinus with arterial supply from branches of the middle meningeal and occipital arteries. There is an important cortical venous reflux, especially into the Labbé vein. C and D, The microcatheter is navigated through the parietal branch of the left middle meningeal artery near the fistula. E and F, The cast of Onyx is seen to extend from middle meningeal artery, occipital artery, fistula, and draining vein. G and H, Post-treatment lateral and anterior angiograms after primitive carotid artery injection show a complete occlusion of the fistula without cortical venous drainage.
procedure-related complication rates, and recurrence rates at follow-up for intracranial DAVFs treated with Onyx via a transarterial approach.
METHODS

Prospective Study Patients
This study was approved by the local ethics committee and was found to conform to scientific principles and research ethics standards. An informed consent was obtained from each patient. This study was designed, conducted, and analyzed without industry assistance, and the article was written independently of industry or any other financial support.
The population was nested within a longitudinal cohort of consecutive patients who were referred to our Neurologic University Hospital for EVT of intracranial DAVFs between January 2013 and December 2015. This prospectively maintained database was queried retrospectively to identify all consecutive patients matching the following inclusion criteria: (a) adult patients with intracranial DAVFs (b) who were treated by transarterial approach using Onyx (EV3) material.
EVT and Initial Angiographic Results
All procedures were performed under general anesthesia and full heparinization (60 IU/kg). Complete selective digital subtraction angiography (DSA) was performed before treatment. An Onyx-compatible microcatheter was coaxially positioned into one of major arterial feeder as close as possible to the fistula site. First, the dead space of the microcatheter was flushed with dimethyl-sulfoxide, followed by a slow injection of Onyx under subtraction fluoroscopy. If an Onyx reflux occurred, the injection was paused for 30 to 60 s. During Onyx progression into the shunt, it was continually and slowly injected. The removal of the microcatheter was done when the Onyx cast stopped advancing or if we had a complete occlusion of the shunt. A postoperative DSA was performed after the procedure to confirm the complete occlusion of the DAVF (Figure 1 ). Initial angiographic results of EVT were classified by a neuroradiologist not involved in the initial treatment (B.G. with 7 yr of experience in interventional neuroradiology) by using the Cognard classification. 22 
Systematic Standard Follow-up Protocol
After discharge, the systematic follow-up included at least a clinical examination and DSA at 3 mo after EVT for ruptured DAVFs and at 6 mo for unruptured DAVFs.
Clinical Follow-up
Further, clinical follow-up data were collected during hospitalization for follow-up DSA or external consultation at 3 mo. Postoperative neurological complication was defined as any new neurological symptoms, including cranial nerve palsy. Procedure-related morbidity was defined as a permanent neurological deficit including cranial nerve palsy or change in modified Rankin Scale (mRS) score ≥ 1 at 3 mo after the procedure.
Image Acquisition and Analysis
Angiographic images were acquired in anteroposterior and lateral projections before and immediately after treatment. Angiographic images obtained immediately after EVT were compared with those obtained at angiographic follow-up. At follow-up, we considered a DAVF recurrence when an early venous opacification was observed at DAVF completely occluded regardless of how big it is. In addition, we also considered it as a recurrence when the type of DAVF was modified.
Systematic Review
We prepared this study in accordance with the Meta-analysis of Observational Studies in Epidemiology and Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, including objectives and plans for collecting and analyzing the data. 23 , 24 We performed a systematic review of the literature by 2 authors (U.S.G. and N.M.) using the keywords "dural arteriovenous fistula" and "onyx" and "cerebral" or "brain" or "intracranial" in MEDLINE and EMBASE databases. Inclusion criteria were the following: all types of study design published in the English language, ≥10 patients, from January 2005 to December 2015, where EVT was performed via a transarterial route and where Onyx was used as the embolic material. Exclusion criteria were the following: case report, studies with duplicate case series, studies with balloon-assisted technique.
Baseline Characteristics of Patients and DAVFs
Clinical data included sex, number of eligible patients, mean age of patients, and clinical presentation. DAVFs characteristics, procedurerelated complications, morbidity and mortality, anatomic outcomes, and follow-up modality. All the data were reviewed and collected individually by 2 authors (S.G.U. and M.N.) and compared. Disagreements were discussed until a consensus was reached.
Outcomes
Only patients treated with Onyx alone were considered for the calculation of the postoperative complications, morbidity, and mortality rates after treatment and DAVF recurrence rates. End points included postoperative neurological deficit after EVT, including cranial nerve palsy, and anatomic results obtained at DSA or magnetic resonance angiography. Postoperative neurological complication was differentiated as ischemic or hemorrhagic.
Individual Study Quality Assessment
The included studies being uncontrolled, individual study quality was assessed using a checklist published by the National Institutes of Health for before-after (pre-post) studies with no control group. 25 This 12-item checklist enables an assessment of uncontrolled studies and provides an overall quality rating. Quality assessment was performed independently by 2 authors (S.G.U. and M.N.).
Statistical Analysis Systematic Review
The 95% confidence intervals (CIs) of the estimates were built with the Wilson method. The estimate and the 95% CI of the mean percentage over all the studies were obtained for each outcome using a logistic mixed model with a random effect on the intercept in order to take into account the heterogeneity between the studies. In all analyses, inconsistency of findings throughout studies was assessed by using the P value and the I 2 statistic. We searched for publication bias using Egger's test for small-study effects and presented funnel plots. The meta-analyses were carried out using the metaprop Stata command on Stata/SE 14.1 (Statacorp LP, College Station, Texas).
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RESULTS
Prospective Study Population
A total of 41 procedures were performed in 33 patients (21 men and 12 women, mean age, 57.4 yr) harboring 36 DAVFs (3 patients had 2 DAVFs). Table 1 provides baseline patient and DAVF characteristics. Initial clinical symptoms were 10 intracranial hemorrhages, 12 tinnitus, and 2 seizures, while the rest of the patients presented with incidentally discovered DAVFs.
Initial Angiographic Results
According to Cognard's classification, 7 cases were type I, 3 cases were type II a, 8 cases were type II b, 2 cases were type II a+b, 8 cases were type III, and 8 cases were type IV. Initial complete exclusion of the DAVFs was obtained in 32 of 36 (88.9%) DAVFs. DAVF obliteration was achieved in 2 procedures for 5 patients and in 1 procedure for the other cases.
Of the 4 partial EVTs, the type of DAVF was initially 1 II a (patient 2), 1 II b (patient 15), 1 III (patient 4), and 1 IV (patient 13). After EVT, the type II b reverted to type II a, and the type III to a type I. For the type IV, the occlusion after EVT was partial because of high risk of facial nerve palsy due to important microcatheter reflux. Thus, considering these 4 patients, 2 procedures were partial due to the risk of nerve palsy or reversion into benign type.
Angiographic Results at Follow-up
Angiography was obtained in 29 patients harboring 31 DAVFs. A recurrence was observed in 4 DAVFs (12.9%). The 10 initially ruptured DAVF were totally occluded at follow-up. A retreatment was performed in 2 DAVFs (6.5%) due to the aggressive type (only via transarterial approach).
For the patients with initial partial obliteration, 2 patients showed similar DAVF type (patients 4 and 15), 1 patient presented complete fistula exclusion at follow-up (patient 13; a complementary surgery was performed after EVT failure), and 1 patient presented a type II b (patient 2). 
Clinical Complications
A total of 3 patients had postoperative neurological complication following EVT. Two patients presented a cranial nerve palsy: 1 had a third cranial nerve palsy after treatment of DAVF type IV located at the anterior temporal lobe with subsequent transitory diplopia and ophthalmoplegia, which completely resolved 3 mo later; and 1 patient had a facial nerve palsy that quickly improved during the first few days, but partially persisted at 3-mo follow-up after treatment of a right lateral sinus fistula type II a+b. After treatment of her second DAVF type II b located in the superior longitudinal sinus, the patient (patient 15) presented with a left hemiplegia due to venous infarction, persistent at follow-up (mRS of 2).
Procedure-Related Morbidity and Mortality
In our prospective cohort, the procedure-related morbidity was 3% (1/33 patients). There was no procedure-related mortality. One patient died due to a compressive hemorrhage in the posterior fossa due to a type III ruptured DAVF. The hematoma was located in the vermis, causing an obstructive hydrocephalus with subsequent ventricular shunt placement. Emergency embolization was performed without complication during procedure, but 1 mo later the patient died from complications of the intracranial hematoma.
Systematic Review
Of the 424 records that were identified in the initial search, 309 were screened after removal of duplicates, and 280 were excluded at title or abstract level. Twenty-nine were articles that were reviewed at full-text out of which 19 studies were selected for final analysis (Figure 2 ). At baseline, 425 patients harboring 463 DAVFs were included. Baseline patient and DAVF characteristics of the 19 included studies are shown in Table 2 summarizes the results of the meta-analysis of the safety and effectiveness of EVT with Onyx (EV3).
Initial Angiographic Results
The overall initial complete occlusion rate was 82% (95% CI, 74%, 88%; Figure 3) . Analysis of the data suggested significant heterogeneity across studies (P < .05), the range of initial complete occlusion rate being 47% to 100%.
Angiographic Results at Follow-up
The recurrence rate was 2% (95% CI, 0%, 5%; Figure 3 ). Recurrence rate was reported at midterm (mean follow-up, 5 mo; range, 3-7.5 mo). Long-term DAVFs recurrences rates were reported in 2 studies comprising a small sample size of 45 patients.
Clinical Complications
The pooled postoperative neurological complications rate was 4% (95% CI: 2%, 6%; I 2 , 0%; Figure 4 ). The pooled rate of postoperative cranial nerve palsy was 2% (95% CI: 1%, 4%; I 2 , 0%; Figure 4 ). The rate of cerebral ischemic and hemorrhagic complications rates were 1% (95% CI: 0%, 2%, I 2 , 0%) and 0% (95% CI: 0%, I 2 , 0%), respectively (Figure, Supplemental Digital Content 3). 
Procedure-Related Morbidity and Mortality
The pooled procedure-related morbidity rate was 3% (95% CI, 1%, 5%; I 2 , 0%; Figure 4 ) with no statistically significant heterogeneity across studies. There were no procedure-related deaths across the 17 studies.
Quality Assessment
Eighteen studies were retrospective whereas 1 was prospective. All were noncomparative. Studies had large heterogeneity in terms of methods for the assessment of outcomes (presence or not of an adjudication committee; presence or not of a centralized core laboratory; time of follow-up). Using the prespecified tool, the quality rating of studies was considered as fair or poor. The main limitations of studies were as follows: no prespecification of selection criteria for the study population; no justification of sample size; no independent assessment of outcome measures across all study participants. Consequently, the risk of bias was significant across studies. Furthermore, we identified potential publication bias on the rate of total complications ( Figure 
DISCUSSION
Based on 19 studies involving a total of 1425 patients with 463 DAVFs, our meta-analysis provides more representative results on DAVF occlusion rates, morbidity, mortality, and complication rates than any single study. The rate of recurrence at midterm follow-up was low after EVT using Onyx (EV3) of intracranial DAVFs (2%, 95% CI: 0%, 5%) in our meta-analysis including our registry data. Although this finding demonstrates the effectiveness of Onyx in the EVT of cranial DAFVs, we observed a nonnegligible rate of DAVF angiographic recurrence (12.9%) at 3to 6 mo in our prospective study. Results at follow-up of intracranial DAVFs beyond 1 yr after EVT are not well known. Longer follow-up periods were reported in 2 studies including only a small number of patients (45 patients). Chandra et al 9 observed no recurrence of 28 patients at 28 mo mean followup, whereas Ambekar et al 4 reported 3 (14.3%) recurrences of 21 patients at 14 mo mean follow-up. 4 This underlines the importance of long-term follow-up for DAVFs, especially for initially ruptured ones with the risk of rebleeding. However, we used DSA, which is the gold standard modality for follow-up of Onyx-treated DAVFs in our study and the series included in the systematic review.
To date, there are several embolic materials to treat DAVFs by endovascular approach including n-butyl-cyanoacrylate (n-BCA), Onyx, polyvinyl alcohol particles, and coils. To date, the best embolic material for cranial DAVFs is not well known and comparative studies with good methodological standard are warranted, which is not the objective in the present study. However, Rabinov et al 20 compared the effectiveness of cranial DAVF EVT with Onyx vs n-BCA in single-center study. Although the sample size was limited (56 fistulas), the initial complete occlusion rate reported for Onyx was 82% vs 33.3% for n-BCA. A superior durability of the occlusion with Onyx on follow-up was observed. In a recent single-center series of 24 fistulas, the authors compared intracranial DAVFs embolization with Onyx vs n-BCA and coils, and they reported initial complete occlusion rate of 66% for Onyx vs 22% for n-BCA. 27 A possible explanation is that DAVFs are complex and heterogenic lesions, with considerable anatomopathological diversity, influencing the difficulty of the access and EVT phase. Furthermore, heterogeneity in operator experience may be another explanation.
Procedure-related morbidity and mortality rates were uniformly low across the studies with pooled rates of 3% (95% CI, 1%, 5%) and 0%, respectively. This meta-analysis, including our registry data, demonstrates the safety of EVT of intracranial DAVFs with Onyx, most morbidity events related to cranial nerve palsy (2%; 95% CI: 1%, 4%). EVT via transarterial approach of lesions close to the skull base, as cranial DAVFs, carries an elevated risk for ischemic nerve injury. 1 As Onyx embolization technique usually utilizes some degree of Onyx reflux, adequate safety margins should be considered appropriately to minimize inadvertent Onyx migration to clinically important vascular branches.
Limitations
Our study had several limitations. First, the articles included in the systematic review contained a majority of retrospective studies with a limited number of patients; some included combined liquid embolic materials. Second, a small number of studies (2 of 20 studies, 45 of 465 patients, 19.6%) with long-term followup were eligible. Third, data presentation was not uniform among the source articles, especially for the procedure-related morbidity definition. Fourth, it is possible that some relevant studies were not taken into account in our systematic review. However, it is unlikely that this potential publication bias strongly distorted our findings because we found no evidence of such bias by examining the funnel plots.
CONCLUSION
EVT of intracranial DAVFs with Onyx (EV3) via transarterial approach is a safe treatment modality. Although Onyx showed a low recurrence rate at mean follow-up of 5 mo, the risk of long-term recurrence is poorly evaluated in our study, and should warrant a longer follow-up period, especially in ruptured cases and neuroaggressive ones.
Disclosure
D
efinitive treatment of dural arteriovenous fistulas (dAVF) requires permanent occlusion of the draining vein. This can be accomplished with either surgery or with a variety of endovascular techniques. For intracranial dAVFs, endovascular treatment is appealing as a lessinvasive alternative to open surgery, and because surgery for many intracranial dAVFs can be complex and challenging. This is the opposite of the situation for spinal dAVFs, for which surgery is usually straightforward and endovascular treatment can be technically challenging. We have come to regard endovascular treatment as first-line for most intracranial dAVFs and surgery first-line for most spinal dAVFs. For spinal dAVFs, this practice was supported by a recent systematic review, which reported initial definitive fistula occlusion in 96.6% of surgery patients and 72.2% of endovascular patients (P < .001). 1 This study also found that recurrence was significantly more likely in endovascular patients.
The authors of the present study present a comprehensive systematic review of endovascular treatment of intracranial dAVFs. The initial occlusion rate of 82%, a mid-term (mean follow-up 5 months) recurrence rate of 2%, and pooled adverse event rate of 4% seem favorable. This study is limited by the lack of surgery comparison group -which is somewhat understandable, given the paucity of intracranial dAVF surgical series, compared to spinal dAVFs -and also because of the possibility of publication bias. This report will serve as a contemporary summary of the risks and benefits of endovascular treatment of intracranial dAVFs for informed consent with patients prior to endovascular treatment.
The usefulness of this study as an aid to clinical decision-making, however, is less clear. Because surgical studies were not included in the analysis, the reader-clinician must consider the endovascular results in this study in light of a sober estimate of the risks and benefits of surgery for intracranial dAVFs from personal experience and other published sources. For example, these reviewers regard surgery as first-line for most anterior fossa dAVFs. These cases are typically straightforward from a neurosurgical standpoint and endovascular treatment, because of the risk of reflux of embolic material into the ophthalmic artery and retinal ischemia, is essentially a circus trick. 2 Furthermore, one cannot make any firm conclusion from this study regarding the efficacy of Onyx (EV3) versus n-BCA for the treatment of intracranial dAVFs. Onyx has become trendy in recent years, partly because of the apparent ease of use of Onyx compared to n-BCA. The use of a "non-adhesive" liquid embolic is perceived as being safer than "adhesive liquid embolics" to operators unaccustomed to n-BCA. Therefore, because Onyx has become more popular in recent years, concomitant improvements and evolution in embolization techniques in recent years can contribute to an appearance of Onxy superiority. We actually favor n-BCA for almost all dAVF embolization procedures, and have only rarely observed fistula recurrence after complete obliteration. Interestingly, the systematic review of spinal dAVFs found a nonsignificantly higher rate of recurrence in patients treated with Onyx compared to n-BCA (P = .13).
